Aurora Cannabis Stock News

Below is a recap of the main news related to the cannabis industry and markets for the week of February 7, 2022. Contents Schumer Urges Senators To Help Finalize Marijuana Legalization Bill No

Aurora is seeing medical cannabis profit margins in excess of 60%.

Aurora Cannabis has become the latest Canadian marijuana producer to post a quarterly loss, saying it lost $75.1 million in the final three months of 2021 as its revenues declined 10%. The Edmonton-based pot company said its consumer cannabis net …

And why it's pulling up Canopy Growth and Tilray marijuana stocks alongside it.

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we mak

Aurora Cannabis (NASDAQ: ACB) (TSX:ACB) released its financial results for the second quarter of fiscal 2022, reporting a net loss of $75.1 million.  Total net revenue amounted to $60.59 million,

Aurora Cannabis (NASDAQ: ACB ) (TSX:ACB) released its financial results for the second quarter of fiscal 2022, reporting a net loss of $75.1 million. Total net revenue amounted to $60.59 million, down by 10% from the same period last year. Adjusted EBITDA was a loss of $9.04 million, compared to a loss of $11.19 million in the same quarter of fiscal 2021. "During the second quarter, we improved our Adjusted EBITDA by $2.5 million over Q1, moving us closer to our profitability goal. Our focus remains on further cost reductions, and we are pleased to announce today that we expect to reach the high end of the $60 to $80 million range," stated Aurora''s CEO Miguel Martin . Over the past 12 months, the company''s stock dropped 63.22%. The Analyst Cantor Fitzgerald’s Pablo Zuanic kept a ‘Neutral’ rating on Aurora stock, lowering the price target to … Full story available on Benzinga.com

Are these short squeeze penny stocks on our watch list right now? The post 4 Short Squeeze Penny Stocks To Buy For Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information

Aurora Cannabis Inc. shares gained in late trading Thursday, after the Canadian pot producer beat sales expectations for the first time in more than a year.

Cantor Fitzgerald analyst Pablo Zuanic on Friday reiterated a neutral rating on Aurora Cannabis and cut his 12-month price target to C$7.60 from C$10.75 due to reduced sales estimates. The company said it expects to reach positive Ebitda by the first half of fiscal year 2023, but Zuanic said the company remains a long-term turnaround story. "We realize pressures in the domestic recreational unit, in part, offset progress in other areas, so trend-wise we are constructive, but do not have enough fodder to upgrade the stock," he said. After the closing bell on Thursday, Aurora Cannabis said its second-quarter loss narrowed to C$75.1 million ($59 million) from more than C$300 million a year ago. Revenue fell to C$60.6 million in the quarter, down from C$67.7 million a year ago. The company''s loss in the latest quarter was wider than the loss of C$45.4 million expected by analysts, but its sales beat the target of $C59.1 million, according to FactSet. Shares of Aurora Cannabis are down 3.3% in premarket trades.

Are these short squeeze penny stocks on our watch list right now? The post 4 Short Squeeze Penny Stocks To Buy For Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information

Cantor Fitzgerald analyst Pablo Zuanic on Friday reiterated a neutral rating on Aurora Cannabis ACB, -1.08% ACB, -1.02% and cut his 12-month price target to C$7.60 from C$10.75 due to reduced sales es

ACB earnings call for the period ending December 31, 2021.

ACB earnings call for the period ending December 31, 2021.